Trials / Enrolling By Invitation
Enrolling By InvitationNCT07286006
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 372 (estimated)
- Sponsor
- Immunovant Sciences GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMVT-1402 | Dose 1 for up to 52 weeks |
Timeline
- Start date
- 2026-01-26
- Primary completion
- 2030-03-01
- Completion
- 2030-03-01
- First posted
- 2025-12-16
- Last updated
- 2026-03-30
Locations
89 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07286006. Inclusion in this directory is not an endorsement.